

TMD8 | 305729

XXXXXXXXXX

**Description**

TMD8 is a monoclonal antibody that targets the BCL-2 protein. It is used in the treatment of B-cell non-Hodgkin's lymphoma (DLBCL). TMD8 is a human IgG1 antibody that binds to the extracellular domain of BCL-2, leading to its degradation and inhibition of its anti-apoptotic activity. TMD8 is used in combination with venetoclax and rituximab in the treatment of DLBCL. TMD8 is also used in the treatment of multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone. TMD8 is a human IgG1 antibody that binds to the extracellular domain of BCL-2, leading to its degradation and inhibition of its anti-apoptotic activity. TMD8 is used in combination with venetoclax and rituximab in the treatment of DLBCL. TMD8 is also used in the treatment of multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone.

**Organism** Human

**Tissue** B cell

**Disease** B-cell non-Hodgkin's lymphoma, multiple myeloma

**Synonyms** TMD-8, BCL-2 antibody, BCL-2 inhibitor

XXXXXXXXXX

**Age** 62 years

**Gender** Male

**Ethnicity** Caucasian

**Growth properties** Stable

XXXXXXXXXX XXXXXXXXXXXXXXXX

**Citation** TMD8 (XXXXX XXXXXXXX Cytion 305729)

**Biosafety level** 1

**NCBI\_TaxID** 9606

**CellosaurusAccession** CVCL\_A442

XXXXXXXXXX XXXX-XXXXXXXXXXXXXX



Product sheet

TMD8 | 305729

**Shipping Conditions** -78°C

**Storage Conditions**

Store at -150 to -196 °C

HLA

**Sterility**